You are viewing the site in preview mode
Skip to main content
| |
Ceritinib (450 mg)
|
Crizotinib
|
Ceritinib vs. Crizotinib
|
|---|
|
Cost (USD)
|
|
Drug and drug administration costs, initial treatment
|
82,215
|
82,623
|
− 408
|
|
Drug and drug administration costs, post-progression treatment
|
10,392
|
9,921
|
471
|
|
Treatment associated adverse event costs
|
1,982
|
1,197
|
785
|
|
Medical costs
|
62,992
|
56,683
|
6,309
|
|
Total costs
|
157,581
|
150,424
|
7,157
|
|
Effectiveness
|
|
Total QALYs
|
3.22
|
2.68
|
0.54
|
|
Total LYs
|
4.51
|
3.85
|
0.66
|
|
Incremental cost-effectiveness ratio (ICER) (USD)
|
|
Incremental cost per QALY gained
| | |
13,343
|
|
Incremental cost per LY gained
| | |
10,794
|
- ICER, incremental cost-effectiveness ratio; LY, Life-year; mg, milligram; QALY, quality-adjusted life year; USD, United States Dollar
